NICE decides not to add dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years to its work programme, as it is covered by the NHSE Commissioning Medicines for Children in Specialised Services Policy .
PIII 52 week VOYAGE RCT (n=408), found those who received add-on dupilumab had fewer asthma exacerbations than those who received placebo (in patients with type 2 inflammatory phenotype, annualised rate was 0.31 vs. 0.75, respectively), as well as better lung function and asthma control .
Manufacturers report positive results for PIII VOYAGE trial (n=408); dupilumab reduced date of severe asthma attacks vs placebo in children with asthma aged 6 to 11 years by between 65% and 59% over one year .
Data from the PIII LIBERTY ASTHMA VOYAGE randomised, double-blind, placebo-controlled trial (n=408 children aged 6 to 12 years. Injection site reactions, viral upper respiratory tract infections and eosinophilia were most common adverse effects. 
PIII Liberty Asthma Excursion trial to evaluate the long-term safety and tolerability of dupilumab SC in children, aged 7 to 12 years with asthma who completed the treatment in the Liberty Asthma Voyage trial starts (NCT03560466). The open-label, single group assignment trial will enrol approximately 236 patients in the US .
PIII Liberty Asthma Voyage trial to assess the efficacy, safety and tolerability of dupilumab SC in children, aged 6 to 11 years, with uncontrolled persistent asthma starts (NCT02948959). The randomised trial will enrol 471 patients in the US and other countries including the EU (not UK). Primary outcome is annualised rate of severe exacerbation events during the placebo-controlled treatment period; collection of these data is due to complete Jul 21 .